Tag: CLIA,Non-Small Cell Lung Cancer,Press Releases,ProTS,blood-based cancer test,cancer diagnostics,lung cancer,molecular diagnostic,oncology,personalized medicine
-
Biodesix Announces Receipt of CLIA Registration Number
Biodesix, Inc. (the “Company”), is pleased to announce receipt of a CLIA registration number 06D1090464 which allows the Company to commercially market VeriStrat®, the serum molecular diagnostic test described in the Journal of the National Cancer Institute 2007 99(11):838-846. The Company is making VeriStrat® available to qualified physicians in locations where the product is compliant with…